{"id":"W2336162936","doi":"10.1200/jco.2013.31.15_suppl.9013","title":"An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Internal medicine; Dacarbazine; Hazard ratio; Progression-free survival; Oncology; Vemurafenib; Melanoma; Clinical endpoint; Adverse effect; Phases of clinical research; Gastroenterology; Chemotherapy; Randomized controlled trial; Confidence interval; Cancer; Cancer research; Metastatic melanoma; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005310706,0.001036279,0.002621073,0.0005412269,0.0003698355,0.001904808,0.001259249,0.002037203,0.006348564],"category_scores_gemma":[0.007424246,0.0005135975,0.003180906,0.0006767585,0.0003777326,0.00132814,0.0006172727,0.004231805,0.001251959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071532,"about_ca_system_score_gemma":0.00136394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001196004,"about_ca_topic_score_gemma":0.006039771,"domain_scores_codex":[0.9978501,0.001376071,0.0001909578,0.0001754685,0.0002921549,0.0001153823],"domain_scores_gemma":[0.9968098,0.001047924,0.001080752,0.0001471374,0.0003993929,0.0005149478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6564174,0.001969506,0.003972702,0.009973047,0.009349126,0.0002688171,0.0003195876,0.0009848584,0.007536028,0.001586346,0.0551921,0.2524304],"study_design_scores_gemma":[0.8950834,0.02870874,0.0100673,0.001483345,0.007691026,0.0004060927,0.00008298433,0.001004055,0.001022576,0.001235218,0.05313883,0.00007654797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4585926,0.3788368,0.009636399,0.04401306,0.01082358,0.02002676,0.04175237,0.001252912,0.03506552],"genre_scores_gemma":[0.7264394,0.1288065,0.01697849,0.04632556,0.005227446,0.02416454,0.03038802,0.0005089156,0.02116109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006348564,"threshold_uncertainty_score":0.02808601,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03970374677695072,"score_gpt":0.3917280835614726,"score_spread":0.3520243367845219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}